Medtronic earns first-of-its-kind FDA labeling for Endurant stent graft

Medtronic (NYSE: MDT)+ announced today that it received new labeling approval from the FDA for its Endurant stent graft system.

The new labeling adds ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removes the rAAA treatment warning. This makes Medtronic the first and only company to remove the rAAA warning from stent graft instructions for use, the company said. It could empower physicians to act confidently in emergency cases, Medtronic says.

A ruptured AAA occurs when the main artery in the abdomen bursts. It can cause severe internal bleeding and require emergency surgical intervention. According to a news release, the mortality rate from a ruptured abdominal aortic aneurysm exceeds 80%. Now, Endurant can offer an option in these emergency cases.

Medtronic — one of the largest medtech companies in the world — began offering Endurant more than a decade ago. It treats AAA through a minimally invasive endovascular repair (EVAR) method. The company says it’s the first and only EVAR system with a decade of global registry outcomes.

Sign up for Blog Updates